Authors

Latest:

SPORE Grant Fuels New Research Projects on Neuroendocrine Tumors

With the FDA emphasis on personalized medicine for patients with orphan diseases, the National Cancer Institute has recently awarded a Neuroendocrine Tumor Specialized Program of Research Excellence to the Holden Comprehensive Cancer Center at the University of Iowa to fund both basic and clinical research on neuroendocrine tumors.

Maciej M. Mrugala, MD, PhD

Latest:

Dr. Mrugala on Extending Treatment With Temozolomide in Glioblastoma

Maciej M. Mrugala, MD, PhD, discusses a retrospective analysis looking at adding cycles of treatment with temozolomide in newly diagnosed patients with glioblastoma.

Maciej Mrugala, MD, PhD, MPH, University of Washington Medical Center

Madelaine Kuiper, MSN, RN

Latest:

Management and Treatment of Interstitial Lung Disease in Breast Cancer

Madelaine Kuiper, MSN, RN, discusses the adverse event of interstitial lung disease, which can occur in patients with HER2-positive metastatic breast cancer who have received fam-trastuzumab deruxtecan-nxki.

Madeleine Duvic, MD

Latest:

Dr. Duvic on Importance of Classifying T-Cell Lymphomas

Madeleine Duvic, MD, professor of Medicine and Dermatology, Blanche Bender Professorship in Cancer Research, director of the Research Fellowship Program, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of classifying T-cell lymphomas and new targets in development. Duvic shared this insight during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.

Madelyn Hanson, PhD

Latest:

Value and Market Access Considerations Often Missing From Trial Design

Having an evidence package at launch that satisfies payersâ€™ value criteria will increase the likelihood that payers will reimburse the drug at a desirable price and enable patient access to innovative treatments.

Madhav Dhodapkar, MBBS

Latest:

Dr Dhodapkar on the Role of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Madhav V. Dhodapkar, MBBS, discusses the advantages and disadvantages of bispecific antibodies and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma, as well as the potential role for the bispecific antibody linvoseltamab in this treatment paradigm.

Madhav V. Dhodapkar, MBBS, Yale

Madhuri Vusirikala, MD

Latest:

Dr. Vusirikala on Hyper-CVAD Plus Ponatinib in Philadelphia Chromosome-Positive ALL

Madhuri Vusirikala, MD, discusses the benefit of hyper-CVAD and ponatinib in patients with Philadelphia chromosome–positive ALL.

Maeve A. Lowery, MD

Latest:

PALB2 Mutations Confer Susceptibility to Familial Pancreatic Cancer and May Provide a Novel Targeted Therapeutic Approach to Cancer

Germline mutations in PALB2 have recently been shown to increase lifetime risk of pancreatic cancer and breast cancer, among other types.

Maggie DiNome, MD

Latest:

Dr. DiNome on Surgical Approaches in Patients With Breast Cancer

Maggie DiNome, MD, associate professor of surgery, University of California, Los Angeles Medical Center, discusses the evolution of surgical approaches in patients with breast cancer.

Maha H. Hussain, MB ChB

Latest:

Hussain and Taplin Talk Gender-Specific Struggles, Career Lessons in GU Oncology

Maha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.

Maha H. Hussain, MD, FACP

Latest:

Dr Hussain on Key Ongoing Clinical Trials in Metastatic Castrate-Resistant Prostate Cancer

Maha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.

Maha Hussain, MD, FACP

Latest:

Dr. Hussain on Retrospective Analysis of the ARASENS trial in mHSPC

Maha H. Hussain, MD, FASCO, FACP, discusses key efficacy and safety data from a secondary analysis of the phase 3 ARASENS trial in metastatic hormone-sensitive prostate cancer.

Maha Hussain, MD, FACP, FASCO

Latest:

Dr. Hussain on Meaningful Effect as an End Point in Prostate Cancer Trials

Maha Hussain, MD, FACP, FASCO, discusses the importance of meaningful effect in prostate cancer trials.

Maisam Fazel, FRCS, MS, MB BChir

Latest:

Dr. Fazel on Trends in Surgical Training

Maisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom on Trends in Surgical Training

Major Lindsey Graham, MD, MC, US Army

Latest:

A Day in the Life of a Military Hematology/ Oncology Fellow

At 5:45 am, the alarm on my phone goes off. I have 20 minutes until my 2 boys wake up, which is just enough time to get ready for work and fix myself a cup of coffee.

Maki Tanioka, MD, PhD

Latest:

Dr. Tanioka on the Results of CALGB 40601 in HER2+ Breast Cancer

Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

Malcolm DeCamp, MD

Latest:

Dr. DeCamp on Platforms of Surgical Management in Lung Cancer

Malcolm McAvoy DeCamp, Jr, MD, chief of Thoracic Surgery in the Department of Surgery, Northwestern University Feinberg School of Medicine, discusses different platforms of surgical management in the treatment of patients with lung cancer.

Malcolm Mason, MD

Latest:

Dr. Mason on Next Steps Following 10-Year PROTECT Study Data in Prostate Cancer

Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses next steps following the 10-year PROTECT study data for patients with prostate cancer.